Relative to infants who received placebo, infants who received choline supplementation were significantly more likely to have intact auditory P50 sensory gating at which evaluation (adjusted for gestational age at birth)?
Genetic markers for variation in α7 nicotinic cholinergic receptor expression were associated with cerebral inhibition in placebo-treated but not choline-treated infants. Studies in DBA/2 mice show a similar relationship between α7 nicotinic cholinergic receptor expression and perinatal choline supplementation. What mechanism of action do these results suggest?
In addition to identifying a correlation with disease, what factors about the use of surrogate markers are widely accepted as critical?